The following products shall be maintained during shipment at the specified temperatures:

(a) Products.

Open Table
Product Temperature
Cryoprecipitated AHF −18 °C or colder.
Measles and Rubella Virus Vaccine Live 10 °C or colder.
Measles Live and Smallpox Vaccine       Do.
Measles, Mumps, and Rubella Virus Vaccine Live       Do.
Measles and Mumps Virus Vaccine Live       Do.
Measles Virus Vaccine Live       Do.
Mumps Virus Vaccine Live       Do.
Fresh Frozen Plasma −18 °C or colder.
Liquid Plasma 1 to 10 °C.
Plasma −18 °C or colder.
Platelet Rich Plasma Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 and 24 °C, if the label indicates storage between 20 and 24 °C.
Platelets Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 to 24 °C, if the label indicates storage between 20 and 24 °C.
Poliovirus Vaccine Live Oral Trivalent 0 °C or colder.
Poliovirus Vaccine Live Oral Type I       Do.
Poliovirus Vaccine Live Oral Type II       Do.
Poliovirus Vaccine Live Oral Type III       Do.
Red Blood Cells (liquid product) Between 1 and 10 °C.
Red Blood Cells Frozen −65 °C or colder.
Rubella and Mumps Virus Vaccine Live 10 °C or colder.
Rubella Virus Vaccine Live       Do.
Smallpox Vaccine (Liquid Product) 0 °C or colder.
Source Plasma −5 °C or colder.
Source Plasma Liquid 10 °C or colder.
Whole Blood Blood that is transported from the collecting facility to the processing facility shall be transported in an environment capable of continuously cooling the blood toward a temperature range of 1 to 10 °C, or at a temperature as close as possible to 20 to 24 °C for a period not to exceed 6 hours. Blood transported from the storage facility shall be placed in an appropriate environment to maintain a temperature range between 1 to 10 °C during shipment.
Yellow Fever Vaccine 0 °C or colder.

(b) Exemptions. Exemptions or modifications shall be made only upon written approval, in the form of a supplement to the biologics license application, approved by the Director, Center for Biologics Evaluation and Research.

[39 FR 39872, Nov. 12, 1974, as amended at 49 FR 23833, June 8, 1984; 50 FR 4133, Jan. 29, 1985; 50 FR 9000, Mar. 6, 1985; 55 FR 11013, Mar. 26, 1990; 59 FR 49351, Sept. 28, 1994; 64 FR 56449, Oct. 20, 1999]


Tried the LawStack mobile app?

Join thousands and try LawStack mobile for FREE today.

  • Carry the law offline, wherever you go.
  • Download CFR, USC, rules, and state law to your mobile device.